MedPath

江西人可医药科技有限公司

Ownership
-
Established
2018-05-22
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

72

NMPA:72

Drug Approvals

Famotidine Injection

Product Name
法莫替丁注射液
Approval Number
国药准字H20253518
Approval Date
Mar 4, 2025
NMPA

Famotidine Injection

Product Name
法莫替丁注射液
Approval Number
国药准字H20253519
Approval Date
Mar 4, 2025
NMPA

Aminophylline Injection

Product Name
氨茶碱注射液
Approval Number
国药准字H20249814
Approval Date
Dec 25, 2024
NMPA

Aminophylline Injection

Product Name
氨茶碱注射液
Approval Number
国药准字H20249813
Approval Date
Dec 25, 2024
NMPA

Xylitol Injection

Product Name
木糖醇注射液
Approval Number
国药准字H20054530
Approval Date
Oct 18, 2024
NMPA

Ganciclovir Injection

Product Name
奥托康
Approval Number
国药准字H20050654
Approval Date
Oct 10, 2024
NMPA

Hemarisin for Injection

Product Name
注射用灵杆菌多糖
Approval Number
国药准字H22026347
Approval Date
Sep 18, 2024
NMPA

Lidocaine Hydrochloride Injection

Product Name
盐酸利多卡因注射液
Approval Number
国药准字H43022081
Approval Date
Oct 8, 2022
NMPA

Lidocaine Hydrochloride Injection

Product Name
盐酸利多卡因注射液(溶剂用)
Approval Number
国药准字H43021924
Approval Date
Oct 8, 2022
NMPA

Hydrocortisone Injection

Product Name
氢化可的松注射液
Approval Number
国药准字H43021212
Approval Date
Jul 11, 2022
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 8
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.